Skip to main content

About us

Our leadership team includes regulatory, healthcare and technology experts supported by an experienced medical advisory board.

Senior Leadership

Kelly Roman

Co-Founder & CEO

For more than a decade, Kelly Roman has helped pioneer the prescription wearable category and has expertise in product development, regulatory affairs, healthcare marketing and clinical trial strategy.

Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.

Charles "Chip" Fisher

Co-Founder & Chairman

Charles “Chip” Fisher grew up in the electronics business - his father, Avery Fisher, founded Fisher Radio (later renamed Fisher Electronics).

After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.

Gordon Levites

Quality Assurance Director

Gordon Levites brings several years of Quality Management System (QMS) experience in medical device controls with a specialty in FDA regulated contract manufacturing for Class II, Non-Sterile, Non-Life Supporting/Life-Sustaining electromechanical products. He has held key positions in both QA and QC workflows, worked to secure good inspectional outcomes with Management Representative duties and has a proven history of collaborating successfully across all organizational levels. Along with a graduate degree in Medical Ethics from New York's flagship Stony Brook University, Gordon brings thoroughness, effectiveness and an absolute dedication to patient safety to the Fisher Wallace QMS.

Diana Aghabekian

Quality Assurance Manager

Diana is an adaptable and experienced QA leader with years of audit and compliance experience, along with knowledge of GxP standards. Diana has leading expertise in Medical Device Quality Management System (eQMS) navigation leveraged to train cross-functional team members and ensure compliance with best practices and regulations. She is a highly analytical and detail-oriented professional with superior communication skills. Diana’s proficiency in gathering data to create informed decisions regarding QMS activities with the PDCA cycle are an indispensable asset to FW. With her proven ability to build productive and cooperative relationships with suppliers, cross-functional teams, and leadership, Diana is the other key management pillar in the FW QMS.

Advisory Board

Simon Webster

Board Member

Simon is CEO of SHUFL Capital, the venture capital firm that recently invested in Fisher Wallace Laboratories. Simon's early career was spent in the UK financial services sector leading business change, delivering technology transformations and supporting M&A transactions.

He led CPA Global on its 20 year journey from a £50m business to its recent public market entry at a value of £6.5bn. Simon has been investing in and working with founders of growth businesses in the SHUFL sectors since 2010.

Peter Rojas


Peter is currently Head of Product, NPE, at Meta, where he incubates the company's new and experimental products. Previously, Peter was a Partner at Betaworks Ventures, which invested in Giphy (sold to Facebook) among other startups, and co-founded the popular tech blogs Engadget and Gizmodo.

In Memoriam

Mitchell Rosenthal


Dear Friends and Colleagues,

Today -- November 19, 2022 -- we mourn the passing of Mitchell Rosenthal, MD, the founder of Phoenix House, the largest private, non-profit therapeutic drug-treatment program in the United States, and a founding medical advisory board member of Fisher Wallace Labs.

He was a constant and thoughtful advisor to the company over the past fifteen years, on many levels, and was instrumental in introducing us to key opinion leaders in the psychiatric and addiction communities.

Mitch believed in our work and the potential of our medical device and arranged to have it used in a remarkable study of 392 patients at Phoenix House in 2009, which showed that with only a modest number of treatments, our device could markedly improve rehab retention (by managing mood and sleep in the first 90 days of residential treatment).

I had the pleasure and honor of serving on the board of the Rosenthal Center, which in his latter years was Mitch’s drug policy non-profit that led the way in creating a dialogue about the importance of the expansion of treatment programs nationwide.

He was a dear and cherished friend and will be missed by so many whose lives he touched.

I hope you will take a moment to read his obituary which appeared this past weekend in the New York Times:

Dr. Mitchell Rosenthal, Phoenix House Founder, Dies at 87 - The New York Times


Chip Fisher
Fisher Wallace Labs

Back to top